Skip to main content
Figure 3 | Respiratory Research

Figure 3

From: Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

Figure 3

Mean changes from baseline in 1-hour morning postdose FEV 1 (A) at week 24 (coprimary endpoint) and (B) over time across duration of study. Analyses were based on a mixed-model for repeated measures. All active treatment groups were significant versus placebo (p< 0.0001) at all study visits. *p< 0.05 versus placebo; §p< 0.05 versus aclidinium, formoterol, and placebo. ACL400/FOR12 FDC, fixed-dose combination of aclidinium 400μg and formoterol 12μg; ACL400/FOR6 FDC, fixed-dose combination of aclidinium 400μg and formoterol 6μg; D1, day 1; D4, day 4; FEV1, forced expiratory volume in 1 second; LS, least squares.

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us